Abstract: However, the presence of M184V/I independently predicted VF of raltegravir- but not dolutegravir-based therapy when compared with a fully-active backbone [adjusted hazard ratio (aHR) = 3.09, P = 0.035], particularly when associated with other non-thymidine analogue mutations (aHR = 27.62, P = 0.004).
Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex with Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study.
Abstract: Major drug resistance mutations were detected in samples from 21 (14.6%) of 144 participants; the most frequent mutations were K103N and M184V/I.
[HIV-1 drug resistance and subtypes in newly reported HIV/AIDS patients before antiretroviral therapy in Taizhou city, 2016-2018].
PMID: 34814456
2021
Zhonghua liu xing bing xue za zhi
Abstract: The resistance mutations of NNRTIs and NRTIs were mainly K103 N (0.7%) and M184I/V (0.5%).
Genetic Diversity and Acquired Drug Resistance Mutations Detected by Deep Sequencing in Virologic Failures among Antiretroviral Treatment Experienced Human Immunodeficiency Virus-1 Patients in a Pastoralist Region of Ethiopia.
Abstract: Among NRTI resistance mutations, M184V (73.2%), K219Q (63.4%) and T215 (56.1%) complex were the most mutated positions, while the most common NNRTI resistance mutations were K103N (24.4%), K101E, P225H and V108I 7.5% each.
Result: Among NRTI resistance mutations, M184V (73.2%), and K219Q, (63.4%) were the most common resistance mutations detected from viraemic subjects, respectively.
Table: M184V
Discussion: A recent global research conducted in an attempt to find a point of care genotypic resistance test to detect HIV-1 drug resistance
Prevalence of Antiretroviral Drug Resistance Mutations Among Pretreatment and Antiretroviral Therapy-Failure HIV Patients in Uzbekistan.
PMID: 32873061
2021
AIDS research and human retroviruses
Abstract: In ART-experienced patients, cohort II, 77.4% (82/106) of viruses contained at least one mutation against PIs, NRTIs, or NNRTIs, with the most common mutations of M184V/I (49.1%; 52/106), K65R (18.9%; 20/106), K103N (23.6%; 25/106), and G190S (22.6%; 24/106).
HIV Pretreatment Drug Resistance Trends in Mexico City, 2017-2020.
Result: The most commonly observed DRMs were K103NS (24.1%) and M184VI (23.3%) in RT.
Discussion: Taking this into consideration, most ADR cases observed in the present study could still be associated with failures to offer efavirenz-based first-line regimens in persons who had not yet switched to INSTI-based options, which is also consistent with the high frequency of K103NS and M184VI observed in persons with ADR.
Evaluation of doravirine-based regimen population target in a large Italian clinical center.
Abstract: Additionally, we experimentally simulated previously reported ETV/3TC resistance for HBV using HIVY115F/F116Y/Q151M with F160M/M184V (L180M/M204V in HBV RT) substituted.
Abstract: Structural analysis of RTY115F/F116Y/Q151M/F160M/M184V:DNA:3TC-TP also demonstrated that the loosely bound 3TC-TP is misaligned at the active site to prevent a steric clash with the side chain gamma-methyl of Val184.
Introduction: 3TC is also approved as an anti-HIV-1 agent, and M184V in HIV-1 RT, which co
M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.
PMID: 32065630
2020
The Journal of antimicrobial chemotherapy
Abstract: BACKGROUND: M184V/I NRTI resistance mutations can be selected by either lamivudine/emtricitabine or abacavir.
Abstract: CONCLUSIONS: M184V/I as a unique NRTI resistance mutation, regardless of possible selection by regimens containing lamivudine/emtricitabine or abacavir, does not affect the virological response of well-controlled patients who switched to abacavir/lamivudine/dolutegravir for at least 12 months.
Abstract: OBJECTIVES: We assessed the efficacy of abacavir/lamivudine/dolutegravir when used in HIV-infected pretreated patients with an undetectable VL who previously harboured M184V/I as a unique NRTI resistance mutation in a genotypic resistance test and had no resistance to
Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.
Result: Result: Nine known DRMs (K65R, V106 M, Y115F, V179 T/E/D, Y181C, M184 V, and G190S) and two potential new DRMs (V75 L and L228R) were demonstrated to be under positive selection pressure (Ka/Ks > 1, LOD > 2).
Result: The NRTI-associated DRMs detected at TF time point in descending order included K65R (57.1%), M184 V/I (47.6%), S68G (26.2%), A62V (14.3%), K70E/R (9.5%), and Y115F (9.5%).
HIV mutation literature information.
PMID: 
2021
HIV medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT